Solentim Establishes New European Entity
Solentim has announced the expansion of its European operations, with the establishment of a new entity in Ireland.
Solentim, a global provider of workflows for antibody and cell-based therapies, has announced the expansion of its European operations, with the establishment of a new entity in Ireland, in a May 5, 2021 press release.
The Irish entity will enable the company to progress with frictionless business within the European Union (EU), now that the United Kingdom is no longer a member. Additionally, the company has revealed that it has opened a new warehousing and logistics hub in Germany to facilitate customer service in the EU.
“Europe is a fast-growing part of our business both in our core therapeutic antibody business and in new development areas including cell and gene therapies,” said Mark Truesdale, CEO, Solentim, in the press release. “This changing therapeutic landscape, in addition to our launch of two major new products, has rapidly increased demand. We want to be closer and more responsive to the needs of the European market and our office in Ireland will ensure ease of operation for customers while our new warehouse facility in Germany will mean that we can deliver products more quickly and easily.”
Source: Solentim
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Pharmaceutical Tariffs Are Imminent: How Industry is Bracing for Impact
April 16th 2025On April 14, 2025, the Trump Administration launched a national security-driven investigation into pharmaceuticals, a move that will likely result in tariffs being placed on pharmaceutical drugs, ingredients, and other components that are imported from outside of the United States.
